Alaunos Therapeutics to Present at the Jefferies Healthcare Conference
June 01 2022 - 8:30AM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), a clinical-stage oncology-focused cell therapy company today
announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew
Deniger, Ph.D., Vice President, Research & Development will
present at the upcoming Jefferies Healthcare Conference being held
on June 8-10, 2022, in New York, NY.
Details for the presentation are below:
Event: Jefferies 2022 Global
Healthcare ConferenceDate: Friday, June 10,
2022Time: 9:00-9:25 am
ETLocation: New York Marriott
MarquisRoom: Track 6
A live webcast of the presentation will be
accessible on the Company’s website in the Investors section under
Events & Presentations at www.alaunos.com or by using the link
here. A replay of the webcast will be available on the Alaunos
website for approximately 90 days following the
presentation.About Alaunos TherapeuticsAlaunos is
a clinical-stage oncology-focused cell therapy company, focused on
developing T-cell receptor (TCR) therapies based on its
proprietary, non-viral Sleeping Beauty gene transfer technology and
its TCR library targeting shared tumor-specific hotspot mutations
in key oncogenic genes including KRAS, TP53 and EGFR. The Company
has clinical and strategic collaborations with The University of
Texas MD Anderson Cancer Center and the National Cancer Institute.
For more information, please visit www.alaunos.com.
Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Sep 2023 to Sep 2024